Syndax Pharmaceuticals (SNDX) investor relations material

Executive summary

• Achieved total revenue of $72.8 million in Q2 2026, up 92% year-over-year, driven by strong commercial performance of Revuforj and Niktimvo, both annualizing above $200 million each.

• Net loss narrowed to $49.4 million in Q2 2026 from $71.8 million in Q2 2025, reflecting higher revenues and controlled expenses.

• Expanded pipeline with two new assets: SNDX-4321 (EGFR inhibitor for NSCLC) and SNDX-62122 (menin inhibitor for myelofibrosis), with IND submissions planned by end of 2026 and 2027.

• Maintained $575 million in cash, cash equivalents, and investments as of June 30, 2026, supporting commercial and R&D priorities through profitability.

• Advanced leadership in menin inhibition, with Revuforj positioned for frontline AML and Niktimvo showing strong adoption in chronic GVHD.

Financial highlights

• Q2 2026 product revenue: $54.7 million (up 91% YoY); Niktimvo collaboration revenue: $18.1 million (up 93% YoY); total revenue: $72.8 million.

• Niktimvo net revenue reached $60.3 million, up 67% year-over-year and 9% sequentially.

• Cost of product sales was $3.2 million; gross margin remains high.

• R&D plus SG&A expense guidance for 2026 is ~$400 million, excluding $50 million in non-cash stock compensation.

• Net loss per share improved to $(0.55) in Q2 2026 from $(0.83) in Q2 2025.

Outlook and guidance

• Expects continued revenue growth from both Revuforj and Niktimvo, advancing toward profitability.

• Topline data from Phase 2 trials of axatilimab in IPF and frontline cGVHD expected in Q4 2026.

• IND submissions for SNDX-4321 and SNDX-62122 planned by end of 2026 and 2027, with early clinical data expected in 2028.

• Anticipates cash, investments, and revenue will enable the company to reach profitability.

• Expense guidance for 2026 is $400 million, excluding $50 million in expected stock option expense.